A randomized clinical trial evaluating 2 types of 1-page educational resources for low back pain found that fact sheets listing treatment options modestly improved patients’ preparedness for shared...
The FDA has approved veligrotug-vvze (Lumvoa) for the treatment of thyroid eye disease regardless of disease activity or duration, based on the pivotal phase 3 THRIVE and THRIVE-2 clinical trials.
In two phase 3, double-blind, placebo-controlled trials of adults with noncirrhotic chronic hepatitis B virus infection receiving stable nucleoside or nucleotide analog therapy, 24 weeks of bepirovirsen...
In an international Bayesian adaptive RCT of adults with MSSA bacteremia, cefazolin was noninferior to flucloxacillin or cloxacillin for 90-day all-cause mortality and was associated with less acute kidney...
Using real-world patient scenarios and current guideline recommendations, this session from Practical Updates in Primary Care outlines a structured primary care approach to diagnosing low back pain,...
IgG4-related disease is unlikely to be the first diagnosis suspected in primary care, but PCPs may be the first clinicians to recognize the atypical, recurrent, mass-like, or multiorgan patterns that should...
The FDA approved ensitrelvir (Xocova) for post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older following contact with an individual with COVID-19.
The FDA approved tebipenem pivoxil (Utebzi) for adults with complicated urinary tract infections, including pyelonephritis, who have limited or no alternative oral treatment options.
Several sessions at the 2026 American Association of Nurse Practitioners National Conference in Las Vegas, NV, addressed migraine-related diagnosis, treatment, red flags, and care considerations across...
In the phase 3a REIMAGINE 1 trial, once-weekly cagrilintide–semaglutide reduced HbA1c vs placebo at 40 weeks in adults with early-stage type 2 diabetes that was inadequately controlled with diet and...
